SCHEMBL30135283

SCHEMBL30135283

Clc1ccccc1C1=CC=NCC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 1/20 0.38
SMN1; SMN2 Q16637 3/20 0.37
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
HPGD P15428 2/20 0.37
TP53 P04637 1/20 0.37
ALDH1A1 P00352 4/20 0.35
LMNA P02545 2/20 0.35
HSD11B1 P28845 1/20 0.35
IDO1 P14902 1/20 0.34
TDP1 Q9NUW8 2/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
HTR7 P34969 2/20 0.33
NOTUM Q6P988 1/20 0.33
LDHA P00338 1/20 0.33
MAPT P10636 1/20 0.33
HTT P42858 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
PTAFR P25105 1/20 0.33
KDM4E B2RXH2 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10507382 0.86 NOTUM (0.37) IDO1NOTUM
SCHEMBL7168168 0.74 CHRNB4 (0.38) SMN1; SMN2NPC1RAB9AHPGDALDH1A1
SCHEMBL1363866 0.70 CYP2A6 (0.38) CYP2A6SMN1; SMN2NPC1RAB9AHPGD
SCHEMBL28911438 0.67 CYP2A6 (0.46) CYP2A6SMN1; SMN2NPC1RAB9AHPGD
SCHEMBL15037613 0.64 DPP4 (0.38) CYP2A6SMN1; SMN2NPC1RAB9AHPGD
SCHEMBL12436776 0.64 MAPT (0.42) SMN1; SMN2TP53LMNANOTUMMAPT
SCHEMBL671133 0.64 CYP2A6 (0.67) CYP2A6SMN1; SMN2NPC1RAB9AHPGD
SCHEMBL29802156 0.64 CYP2A6 (0.67) CYP2A6SMN1; SMN2NPC1RAB9AHPGD
SCHEMBL29883244 0.64 CYP2A6 (0.67) CYP2A6SMN1; SMN2NPC1RAB9AHPGD
SCHEMBL2728153 0.64

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12600711-B2 Triazacyclododecansulfonamide (TCD)-based protein secretion inhibitors KEZAR LIFE SCIENCES, INC. (US) 2026-04-14 US disclosed
US-20220402891-A1 TRIAZACYCLODODECANSULFONAMIDE (TCD)-BASED PROTEIN SECRETION INHIBITORS ENODIA THERAPEUTICS SAS (FR) 2022-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220402891-A1 TRIAZACYCLODODECANSULFONAMIDE (TCD)-BASED PROTEIN SECRETION INHIBITORS SEC61B, SEC61A1, SEC61G CYP2A6 707/4885SMN1; SMN2 4499/4885NPC1 183/4885
US-12600711-B2 Triazacyclododecansulfonamide (TCD)-based protein secretion inhibitors CD274, CD40, ICOS CYP2A6 3363/4885SMN1; SMN2 3254/4885NPC1 993/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.